Sociodemographic and clinical features of HCs and patients with ALSa
| Healthy Controls | Patients with ALS | Pa | |
|---|---|---|---|
| No. | 14 | 23 | |
| Age (yr) | 60 ± 11 (43–76) | 61 ± 10 (40–78) | .84 |
| Women | 8 (57%) | 11 (48%) | .74 |
| r-ALSFRS score | 33.0 ± 6.8 (22–46) | ||
| Disease duration (mo) | 24.4 ± 18.6 (3–72) | ||
| Progression rate | 1.0 ± 1.0 (0.2–3.7) | ||
| UL-MRC score | 56.6 ± 11.0 (39–70) | ||
| LL-MRC score | 35.9 ± 13.8 (2–50) | ||
| UMN score | 13.2 ± 3.9 (3–16) |
a T test or Pearson χ2 test as appropriate. Values are mean ± SD (range) and No. (percentage). Progression rate was calculated as follows: (48 − r-ALSFRS score) / months of disease duration.